You are Beatriz, 55, CEO of Farmonet, a Spanish-listed specialty pharma firm. It is February. The annual letter to shareholders is due in 12 days. It is going out at the end of the worst fiscal year of your tenure.
The situation
Farmonet ended FY -€48M in net income (against +€72M the year before). The headline event was the Phase III failure of Vendrina, your lead oncology candidate — written off €120M in capitalized R&D. Revenue from the existing portfolio held flat at €620M. Two product-liability lawsuits relating to an older drug remain unresolved. Two non-exec directors resigned mid-year over governance disagreements (the disagreements were never made public).
Beyond the numbers: the share price is −34% YTD. Analyst coverage is split — three Buy, four Hold, two Sell. The 2,400 employees read the letter on internal-comms day; it shapes the year's narrative inside the firm. Major institutional investors will dial in to the post-letter call. The letter is the most-read piece of CEO communication you will produce all year.